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SUPPLEMENTARY NOTES
ABSTRACT
Dendritic cells (DCs), recognized as major antigen presenting cells, are uniquely equipped to initiate and regulate immune responses, making them a key target for developing new therapies. Although ex vivo DC therapy has shown promise, it is a customized, complex, patient-specific cell therapy that reduces its universal applicability for cancer. Directly targeting antigens to DCs in vivo will facilitate the development of an "off-the-shelf" tumor vaccine that circumvents the need for ex vivo DC loading. DCs express a number of specialized endocytic receptors of the C-type lectin family enabling capture of antigen by receptor-mediated endocytosis at very low concentrations. To deliver antigens to DCs in vivo, we developed artificial receptor ligands to the macrophage mannose receptor (MMR or CD206) , an endocytic C-type lectin receptor expressed on DCs and macrophages. An RNA aptamer library comprised of 40 randomized nucleotides and modified with 2´Fluoro-modified pyrimidines for improved nuclease resistance was selected for affinity binding to MMR. A complex selection scheme with alternating rounds on both, recombinant human and murine MMR, as well as on cells engineered to express human MMR enabled us to identify cross-reactive aptamers that recognize MMR with high affinity. A truncated, minimal version of the identified aptamer with retained receptor-binding properties gets rapidly internalized into human monocyte-derived DCs in vitro. Milestone 2: Generate aptamers for the study.
(1-9 months) 1. Using 12 rounds of SELEX (systematic evolution of ligands by exponential enrichment), we identified RNA aptamers that bind the endocytic macrophage mannose receptor (MMR) receptors expressed on murine and human DC with high affinity and excellent specificity (Figure 1 ). The SELEX procedure ("toggle-SELEX") was designed to enable the identification of aptamers that cross-react with the extracellular domains of both, murine and human MMR (mMMR and hMMR), which share 83% homology. 2.
The identified lead aptamer, #14 (length: 71 nucleotides [nt]), was truncated to a 49nt version (#14A) with retained MMR-binding characteristics (Figure 2A and 2C) , which allows efficient chemical synthesis. The introduction of two point mutations within a loop region of #14A resulted in a nonbinding aptamer version, #14A_mut1, without altering the predicted secondary structure ( Figure 2B and 2C). This aptamer serves as negative control in current and future experiments. Flow cytometry assays using fluorescent-labeled #14 confirmed that the aptamer recognizes MMR in its native confirmation expressed on the surface of monocyte-derived human DCs (moDC; Figure 3A) . Maturation of moDCs using a cytokine cocktail (mDC) leads to reduced cell staining efficiency as compared to immature DCs (imDC), which agrees with reports that DCs down regulate antigen capturing receptors, such as MMR, upon maturation. Moreover, the cell staining profile of the truncate #14A on imDC was found to be indistinguishable from the parental full-length aptamer ( Figure 3C ).
2.
We further investigated uptake of fluorescent-labeled #14A into imDC upon binding to surface expressed MMR, which is a prerequisite to our overall goal to deliver tumor-antigens to DC in vivo. Incubation of imDC with #14A at 4⁰C (which abrogates receptor internalization) results in efficient cell staining, but the signal is lost upon treatment with RNase ( Figure 4, left panel) . In contrast, the cell staining profile of #14A on imDC at 37⁰C is not affected by RNase treatment, which indicates efficient receptor-mediated uptake of the aptamer into subcellular compartments (Figure 4, right panel) . 3.
We currently characterize the subcellular localization of aptamers internalized into imDC in more detail using confocal microscopy.
4.
The uptake of #14A into murine DCs has not been studied so far, since we could not detect prominent MMR expression on easily accessible murine cell types, such as bone marrow-derived DC, primary splenocytes, or murine DC-derived cell lines (e.g. JAWS II, DC2.4). However, we identified high levels of MMR expressed on ~ 50% of lymph node resident CD11C + cells (data not shown), which supports the assumption that assessing the effect of antigen targeting to MMR expressing DC in murine immunotherapy models, as suggested in our proposal, is feasible. Since the induction of potent T cell responses positively correlates with the number antigenic peptides displayed in the context of major histocompatibility complex (MHC) class I and class II molecules, we compared the protein yield of mRNAs harboring a series of nucleobase modifications after transfection into different cell types. From all tested modifications, mRNAs incorporating either pseudouridine (ψ) or 5-methylcytidine (5mC) resulted in the highest translational output, with a 1.6-and 3.0-fold increase in protein yield, respectively, as compared to unmodified mRNA ( Figure 5 ). 2.
To establish aptamer-mRNA chimeras, we developed an optimized protocol to anneal #14A with a 25nt uridine extension at the 3'end to poly-adenylated mRNAs of choice (data not shown). #14A annealed to the poly-A tail of a 5mC-modified mRNA, radiolabeled at its 5'end, and encoding MART-1 is able to bind hMMR in vitro and efficiently tethers the mRNA to the protein (Figure 6 ).
3.
We currently compare the intracellular localization and fate of internalized untargeted mRNA to MMR-targeted mRNA using confocal microscopy. Moreover, we investigate whether luciferase reporterencoding mRNA targeted to MMR results in higher translational yield in imDC as compared to untargeted mRNA. 4.
Besides our attempts to deliver mRNA to DC by means of aptamer #14A, we tested the capability of #14A to target protein antigens to DC. #14A-mediated protein delivery serves as internal quality control for the performance of our aptamer. As shown in Figure 7 , we were able to specifically deliver a proteincomplex consisting of chicken ovalbumin conjugated to IgG (molecular weight ~ 200kDa) to imDC using the MMR-targeting aptamer #14. 10 µg of unmodified, pseudouridine modified (ψ), 5-methyl-cytosine modified (5mC), or 5mC + ψ modified mRNA encoding luciferase was transfected into RAW 267.4 cells using Lipofectamine 2000. The luciferase activity in cell lysates was determined after 24h and normalized to the activity of unmodified mRNA (mean of one experiment carried out in triplicate is shown). were transcribed with a 25nt polyU extension at the 3' end and annealed to the polyA-tails of either unmodified, pseudouridine modified (ψ), or 5-methyl-cytosine modified (5mC) modified mRNA (γ-ATPlabeled at the 5' end). Binding of the resulting aptamer-mRNA chimeras to recombinant hMMR protein was determined by nitrocellulose filter binding. . The OVAdelivery reagent consists of a biotin-binding IgG-antibody (black) conjugated to full-length OVA protein (blue, egg-shaped symbol) and FITC-fluorophore (green, star-shaped symbol). This conjugate can be captured on 5' biotinylated aptamer (indicated by an arrow). (B) 5' biotinylated aptamers #14A_mut1 and #14A were allowed to bind imDC at 4 C for 20 min in quadruplicate. The cells were washed to remove unbound aptamers and further incubated with the OVA-delivery reagent (reagent) for capture on cell surface bound aptamers at 4 C. Two samples of each quadruplicate were further incubated at 4 C, while the remaining two samples were incubated at 37 C for 15 min to allow for receptor internalization. One of each duplicate samples incubated at either 4 C (left panel) or 37 C (right panel), respectively, was treated with RNase to remove cell surface bound aptamer/reagent complexes, the cells washed, and analyzed by flow cytometry. Fluorescent signals obtained in the presence of RNase represent protein complexes that have been internalized into the cell via the MMR-targeting aptamer #14A (dark blue population in the right panel).
KEY RESEARCH ACCOMPLISHMENTS:
Milestones achieved during the first year of funding as outlined in the Statement of Work (SOW): Milestone #1: Obtained IACUC-(animal work) and IRB-(human work) protocol approval. Milestone #2: Generated mouse and human MMR targeting aptamer for the study.
